The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Very important pharmacogene summary
Open accessAbstract
Hodges, Laura M.; Markova, Svetlana M.; Chinn, Leslie W.; Gow, Jason M.; Kroetz, Deanna L.; Klein, Teri E.; Altman, Russ B. Author Information
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A haplotype map of the human genome
The International HapMap Consortium (2005) · Nature · doi:10.1038/nature04226 · Cited by 5,858
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,365
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Mammalian ABC Transporters in Health and Disease
Borst, P., & Elferink, R. O. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.102301.093055 · Cited by 1,571
Identification of functionally variant MDR1 alleles among European Americans and African Americans
Kim, R. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.117412 · Cited by 1,009
ABC Multidrug Transporters: Structure, Function and Role in Chemoresistance
Sharom, F. J. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.1.105 · Cited by 973
Thomas, H., & Coley, H. M. (2003) · Cancer Control · doi:10.1177/107327480301000207 · Cited by 931
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
Marzolini, C. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.012 · Cited by 895
Multiple molecular mechanisms for multidrug resistance transporters
Higgins, C. F. (2007) · Nature · doi:10.1038/nature05630 · Cited by 860
Wacher, V. J., Wu, C., & Benet, L. Z. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940130302 · Cited by 857
van Helvoort, A., Smith, A. J., Sprong, H., Fritzsche, I., Schinkel, A. H., Borst, P., & van Meer, G. (1996) · Cell · doi:10.1016/s0092-8674(00)81370-7 · Cited by 855
Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines
Riordan, J. R., Deuchars, K., Kartner, N., Alon, N., Trent, J., & Ling, V. (1985) · Nature · doi:10.1038/316817a0 · Cited by 826
Drug-Like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization
Kerns, E. H., & Di, L. (2016) · Cited by 784
The multidrug transporter, a double-edged sword.
Gottesman, M. M., & Pastan, I. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)37730-5 · Cited by 757
Biedler, J. L., & Riehm, H. (1970) · PubMed · Cited by 747
Cascorbi, I. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114164 · Cited by 747
Genotype, haplotype and copy-number variation in worldwide human populations
Jakobsson, M., Scholz, S. W., Scheet, P., Gibbs, J. R., VanLiere, J. M., Fung, H.-C., Szpiech, Z. A., Degnan, J. H., Wang, K., Guerreiro, R., et al. (2008) · Nature · doi:10.1038/nature06742 · Cited by 714
Siddiqui, A., Kerb, R., Weale, M. E., Brinkmann, U., Smith, A., Goldstein, D. B., Wood, N. W., & Sisodiya, S. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021986 · Cited by 665
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition
Zhou, S.-F. (2008) · Xenobiotica · doi:10.1080/00498250701867889 · Cited by 599
Importance of P-glycoprotein at blood–tissue barriers
Fromm, M. F. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.06.002 · Cited by 592
The ABC transporter structure and mechanism: perspectives on recent research
Jones, P. M., & George, A. M. (2004) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3336-9 · Cited by 578
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability
Wang, D., Johnson, A. D., Papp, A. C., Kroetz, D. L., & Sadée, W. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000178311.02878.83 · Cited by 490
Self-citationChan, H. S., Thorner, P. S., Haddad, G., & Ling, V (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.4.689 · Cited by 451
P-Glycoprotein Expression as a Predictor of the Outcome of Therapy for Neuroblastoma
Chan, H. S. L., Haddad, G., Thorner, P. S., DeBoer, G., Lin, Y. P., Ondrusek, N., Yeger, H., & Ling, V. (1991) · New England Journal of Medicine · doi:10.1056/nejm199112053252304 · Cited by 441
Custodio, J. M., Wu, C.-Y., & Benet, L. Z. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.043 · Cited by 434
Kroetz, D. L., Pauli-Magnus, C., Hodges, L. M., Huang, C. C., Kawamoto, M., Johns, S. J., Stryke, D., Ferrin, T. E., DeYoung, J., Taylor, T., et al. (2003) · Pharmacogenetics · doi:10.1097/00008571-200308000-00006 · Cited by 429
Self-citationIncreased drug delivery to the brain by P-glycoprotein inhibition
Sadeque, A. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109156 · Cited by 426
Impact of P-glycoprotein on clopidogrel absorption
Taubert, D., VONBECKERATH, N., Grimberg, G., Lazar, A., JUNG, N., Goeser, T., Kastrati, A., Schömig, A., & Schömig, E. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.07.007 · Cited by 420
Role of Multidrug Transporters in Pharmacoresistance to Antiepileptic Drugs
Löscher, W., & Potschka, H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.7 · Cited by 409
Miller, D. S., Bauer, B., & Hartz, A. M. S. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07109 · Cited by 392
Multidrug resistance transporters and modulation
Tan, B., Piwnica-Worms, D., & Ratner, L. (2000) · Current Opinion in Oncology · doi:10.1097/00001622-200009000-00011 · Cited by 384
Uhr, M., Tontsch, A., Namendorf, C., Ripke, S., Lucae, S., Ising, M., Dose, T., Ebinger, M., Rosenhagen, M., Kohli, M., et al. (2008) · Neuron · doi:10.1016/j.neuron.2007.11.017 · Cited by 382
Herbal Modulation of P‐Glycoprotein
Zhou, S., Lim, L. Y., & Chowbay, B. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-120028427 · Cited by 375
Hitzl, M., Drescher, S., van der Kuip, H., Schäffeler, E., Fischer, J., Schwab, M., Eichelbaum, M., & Fromm, M. F. (2001) · Pharmacogenetics · doi:10.1097/00008571-200106000-00003 · Cited by 374
ABC proteins : from bacteria to man
Holland, I. B., Cole, S. P. C., Kuchler, K., & Higgins, C. F. (2003) · Medical Entomology and Zoology · Cited by 361
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor
Fox, E., & Bates, S. E. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.4.447 · Cited by 350
Rosenberg, M. F., Callaghan, R., Ford, R. C., & Higgins, C. F. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.16.10685 · Cited by 345
A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function
Fung, K. L., & Gottesman, M. M. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.02.014 · Cited by 335
P-Glycoproteins and Multidrug Resistance
Bellamy, W. T. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.001113 · Cited by 319
Several major antiepileptic drugs are substrates for human P-glycoprotein
Luna-Tortós, C., Fedrowitz, M., & Löscher, W. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.032 · Cited by 310
Genetic Polymorphisms of the Human MDR1 Drug Transporter
Schwab, M., Eichelbaum, M., & Fromm, M. F. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140233 · Cited by 308
Leschziner, G. D., Andrew, T., Pirmohamed, M., & Johnson, M. R. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500413 · Cited by 300
Tang, K., Ngoi, S.-M., Gwee, P.-C., Chua, J. M. Z., Lee, E. J. D., Chong, S. S., & Lee, C. G. L. (2002) · Pharmacogenetics · doi:10.1097/00008571-200208000-00004 · Cited by 285
Marchetti, S., Mazzanti, R., Beijnen, J. H., & Schellens, J. H. M. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-927 · Cited by 284
Collnot, E.-M., Baldes, C., Wempe, M. F., Kappl, R., Hüttermann, J., Hyatt, J. A., Edgar, K. J., Schaefer, U. F., & Lehr, C.-M. (2007) · Molecular Pharmaceutics · doi:10.1021/mp060121r · Cited by 280
Schuetz, E. G., Furuya, K. N., & Schuetz, J. D. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12089-2 · Cited by 265
Irinotecan pathway genotype analysis to predict pharmacokinetics.
Mathijssen, R. H. J., Marsh, S., Karlsson, M. O., Xie, R., Baker, S. D., Verweij, J., Sparreboom, A., & McLeod, H. L. (2003) · PubMed · Cited by 258
Haas, D. W., Smeaton, L. M., Shafer, R. W., Robbins, G. K., Morse, G. D., Labbé, L., Wilkinson, G. R., Clifford, D. B., D’Aquila, R. T., De Gruttola, V., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/497610 · Cited by 257
MDR1 gene polymorphisms and disposition of the P‐glycoprotein substrate fexofenadine
Drescher, S., Schaeffeler, E., Hitzl, M., Hofmann, U., Schwab, M., Brinkmann, U., Eichelbaum, M., & Fromm, M. F. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01591.x · Cited by 249
The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans
Fromm, M. F. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00064-9 · Cited by 247
MDR1 Ala893 Polymorphism Is Associated with Inflammatory Bowel Disease
Brant, S. R., Panhuysen, C. I. M., Nicolae, D., Reddy, D. M., Bonen, D. K., Karaliukas, R., Zhang, L., Swanson, E., Datta, L. W., Moran, T., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/379927 · Cited by 236
An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Takara, K., Sakaeda, T., & Okumura, K. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206775201965 · Cited by 236
Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs
Sakaeda, T., Nakamura, T., & Okumura, K. (2003) · Pharmacogenomics · doi:10.1517/phgs.4.4.397.22747 · Cited by 231
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein
Pauli-Magnus, C., Rekersbrink, S., Klotz, U., & Fromm, M. F. (2001) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-001-0489-7 · Cited by 230
Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy
Tan, N. C. K., Heron, S. E., Scheffer, I. E., Pelekanos, J. T., McMahon, J. M., Vears, D. F., Mulley, J. C., & Berkovic, S. F. (2004) · Neurology · doi:10.1212/01.wnl.0000137051.33486.c7 · Cited by 211
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Terwogt, J. M. M., Malingré, M. M., Beijnen, J. H., Huinink, W. W. T. B., Rosing, H., Koopman, F. J., van Tellingen, O., Swart, M., & Schellens, J. H. M. (1999) · PubMed · Cited by 205
Cyclosporins as drug resistance modifiers
Twentyman, P. R. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90668-9 · Cited by 201
Yamauchi, A., Ieiri, I., Kataoka, Y., Tanabe, M., Nishizaki, T., Oishi, R., Higuchi, S., Otsubo, K., & Sugimachi, K. (2002) · Transplantation · doi:10.1097/00007890-200208270-00024 · Cited by 184
Multidrug resistance ABC transporters
Chang, G. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01085-8 · Cited by 177
Clinical Aspects of the MDR1 (ABCB1) Gene Polymorphism
Eichelbaum, M., Fromm, M. F., & Schwab, M. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200404000-00017 · Cited by 176
Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy
Zimprich, F., Sunder-Plassmann, R., Stogmann, E., Gleiss, A., Dal-Bianco, A., Zimprich, A., Plumer, S., Baumgartner, C., & Mannhalter, C. (2004) · Neurology · doi:10.1212/01.wnl.0000141021.42763.f6 · Cited by 171
Litman, T., Zeuthen, T., Skovsgaard, T., & Stein, W. D. (1997) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(97)00027-6 · Cited by 164
Robey, R. W., Shukla, S., Finley, E. M., Oldham, R. K., Barnett, D., Ambudkar, S. V., Fojo, T., & Bates, S. E. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.12.001 · Cited by 158
Kuo, M. T. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2008.2095 · Cited by 152
Gerloff, T., Schaefer, M., Johne, A., Oselin, K., Meisel, C., Cascorbi, I., & Roots, I. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01691.x · Cited by 151
Kolitz, J. E., George, S. L., Dodge, R. K., Hurd, D. D., Powell, B. L., Allen, S. L., Vélez-García, E., Moore, J. O., Shea, T. C., Hoke, E. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.106 · Cited by 150
Asano, T., Takahashi, K. A., Fujioka, M., Inoue, S., Okamoto, M., Sugioka, N., Nishino, H., Tanaka, T., Hirota, Y., & Kubo, T. (2003) · Pharmacogenetics · doi:10.1097/00008571-200311000-00003 · Cited by 143
Sai, K., Kaniwa, N., Itoda, M., Saito, Y., Hasegawa, R., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Shirao, K., et al. (2003) · Pharmacogenetics · doi:10.1097/00008571-200312000-00005 · Cited by 143
Polymorphisms in the ABC drug transporter gene MDR1
Brinkmann, U., & Eichelbaum, M. F. (2001) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500001 · Cited by 141
Identification of Novel Substrates for Human Cytochrome P450 2J2
Lee, C. A., Neul, D., Clouser-Roche, A., Dalvie, D., Wester, M. R., Jiang, Y., Jones, J. P., Freiwald, S., Zientek, M. A., & Totah, R. A. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.030270 · Cited by 138
Schaich, M. A., Kestel, L., Pfirrmann, M., Robel, K., Illmer, T., Krämer, M., Dill, C., Ehninger, G., Schackert, G., & Krex, D. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn548 · Cited by 133
DRUG RESISTANCE AND MEMBRANE ALTERATION IN MUTANTS OF MAMMALIAN CELLS
Ling, V. W. T. (1975) · Canadian Journal of Genetics and Cytology · doi:10.1139/g75-064 · Cited by 128
P‐glycoprotein: So Many Ways to Turn It On
Callaghan, R., Crowley, E. H., Biochem, M., Potter, S., & Kerr, I. D. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007311568 · Cited by 126
Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities
Morita, N., Yasumori, T., & Nakayama, K. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00178-3 · Cited by 122
Nikisch, G., Eap, C. B., & Baumann, P. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.09.010 · Cited by 122
Kalitsky, J., Shayeganpour, A., Brocks, D. R., & Piquette‐Miller, M. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.1.20 · Cited by 120
Brooks, T. A., Minderman, H., O’Loughlin, K. L., Pera, P. J., Ojima, I., Baer, M. R., Bernacki, R. J., & Brooks, T. A. (2003) · PubMed · Cited by 119
Complex Haplotypic Effects of the ABCB1 Gene on Epilepsy Treatment Response
Hung, C., Tai, J. J., Lin, C., Lee, M., & Liou, H. (2005) · Pharmacogenomics · doi:10.1517/14622416.6.4.411 · Cited by 116
Woodahl, E. L., & Ho, R. J. Y. (2004) · Current Drug Metabolism · doi:10.2174/1389200043489108 · Cited by 112
The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone
Karssen, A. M., Meijer, O. C., van der Sandt, I. C. J., Boer, A. D., de Lange, E. C. M., & de Kloet, E. R. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1750251 · Cited by 112
Fischer, V., Rodríguez‐Gascón, A., Heitz, F., Tynes, R. E., Hauck, C., Cohen, D., & Vickers, A. E. M. (1998) · PubMed · Cited by 111
Interactions of Human P-glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin
Hochman, J. H., Pudvah, N. T., Qiu, J., Yamazaki, M., Tang, C., Lin, J. H., & Prueksaritanont, T. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000041466.84653.8c · Cited by 109
Planting, A. S. T., Sonneveld, P., van der Gaast, A., Sparreboom, A., van der Burg, M. E. L., Luyten, G. P. M., Leeuw, K. D., de Boer-Dennert, M. M., Wissel, P. S., Jewell, R. C., et al. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0854-6 · Cited by 107
Hauswald, S., Duque‐Afonso, J., Wagner, M. M., Schertl, F. M., Lübbert, M., Peschel, C., Keller, U. B., & Licht, T. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2048 · Cited by 107
Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese
Kwan, P., Baum, L., Wong, V. C. N., Ng, P. W., Lui, C. H. T., Sin, N. C., Hui, A. C.-F., Yu, E., & Wong, K. S. (2007) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2007.04.013 · Cited by 105
Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi.
Chen, C. C., Meadows, B., Regis, J. T., Kalafsky, G., Fojo, T., Carrasquillo, J. A., & Bates, S. E. (1997) · PubMed · Cited by 102
The Star-Allele Nomenclature: Retooling for Translational Genomics
Robarge, J., Li, L., Desta, Z., Nguyen, A., & Flockhart, D. A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100284 · Cited by 101
Ethnicity-Related Polymorphisms and Haplotypes in the Human ABCB1 Gene
Kimchi‐Sarfaty, C., Marple, A., Shinar, S., Kimchi, A. M., Scavo, D., Roma, M. I., Kim, I., Jones, A., Arora, M., Gribar, J. J., et al. (2006) · Pharmacogenomics · doi:10.2217/14622416.8.1.29 · Cited by 101
Drug–drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1)
Aszalós, A. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.021 · Cited by 93
Nebert, D. W. (2000) · Pharmacogenetics · doi:10.1097/00008571-200006000-00001 · Cited by 92
Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration
Aarnoudse, A. L. H. J., Dieleman, J. P., Visser, L. E., Arp, P., van der Heiden, I. P., van Schaik, R. H. N., Molokhia, M., Albert Hofman, D., Uitterlinden, A. G., & Stricker, B. H. C. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f70458 · Cited by 91
Multidrug Resistance Protein 2 Is an Important Determinant of Paclitaxel Pharmacokinetics
Lagas, J. S., Vlaming, M. L. H., van Tellingen, O., Wagenaar, E., Jansen, R. S., Rosing, H., Beijnen, J. H., & Schinkel, A. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1352 · Cited by 91
van den Heuvel‐Eibrink, M. M., Wiemer, E. A. C., de Boevere, M. J., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3605 · Cited by 89
Choo, E. F., Kurnik, D., Muszkat, M., Ohkubo, T., Shay, S. D., Higginbotham, J. N., Glaeser, H., Kim, R. B., Wood, A. J. J., & Wilkinson, G. R. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.099648 · Cited by 84
Takane, H., Kobayashi, D., Hirota, T., Kigawa, J., Terakawa, N., Otsubo, K., & Ieiri, I. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.069724 · Cited by 81
Drug-Herb Interactions: Eliminating Toxicity with Hard Drug Design
Yang, X.-X., Hu, Z., Duan, W., Zhu, Y. Z., & Zhou, S.-F. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206779010440 · Cited by 73
Owen, A., Goldring, C. E., Morgan, P., et al. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02229.x · Cited by 72
Leschziner, G. D., Zabaneh, D., Pirmohamed, M., Owen, A., Rogers, J., Coffey, A. J., Balding, D. J., Bentley, D., & Johnson, M. R. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000197467.21964.67 · Cited by 71
Bates, S. E., Bakke, S., Kang, M. H., Robey, R. W., Zhai, S., Thambi, P. M., Chen, C. C., Patil, S., Smith, T., Steinberg, S. M., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0829-03 · Cited by 71
The expression of efflux and uptake transporters are regulated by statins in Caco-2 and HepG2 cells
Rodrigues, A. C., Curi, R., Genvigir, F. D. V., Hirata, M. H., & Hirata, R. D. C. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.85 · Cited by 69
Induction of Multiple Drug Transporters by Efavirenz
Weiß, J., Herzog, M., König, S. K., Storch, C. H., Ketabi‐Kiyanvash, N., & Haefeli, W. E. (2009) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08209fp · Cited by 68
Role of drug efflux carriers in the healthy and diseased brain
Hermann, D. M., Kılıç, E., Spudich, A., Krämer, S. D., Wunderli‐Allenspach, H., & Bassetti, C. L. (2006) · Annals of Neurology · doi:10.1002/ana.21012 · Cited by 64
Seneca, N. M., Zoghbi, S. S., Liow, J., Kreisl, W. C., Herscovitch, P., Jenko, K. J., Gladding, R. L., Taku, A., Pike, V. W., & Innis, R. B. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058453 · Cited by 62
Kruijtzer, C. M. F., Schellens, J. H. M., Mezger, J. M., Scheulen, M. E., Keilholz, U., Beijnen, J. H., Rosing, H., Mathôt, R. A. A., Marcus, S., van Tinteren, H., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.058 · Cited by 59
Seigneuret, M., & Garnier-Suillerot, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302443200 · Cited by 58
P-glycoprotein structure and evolutionary homologies
Bosch, I., & Croop, J. M. (1998) · Cytotechnology · doi:10.1023/a:1008080911522 · Cited by 58
Involvement of Vitamin D Receptor in the Intestinal Induction of Human ABCB1
Tachibana, S., Yoshinari, K., Chikada, T., Toriyabe, T., Nagata, K., & Yamazoe, Y. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027219 · Cited by 58
MDR1 Gene Polymorphisms and Phase 1 Viral Decay During HIV-1 Infection
Haas, D. W., Wu, H., Li, H., Bosch, R. J., Lederman, M. M., Kuritzkes, D. R., LANDAY, A. L., Connick, E., Benson, C. A., Wilkinson, G. R., et al. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200311010-00006 · Cited by 57
Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo
Szabó, D., Szabó, G., Ocsovszki, I., Aszalós, A., & Molnár, J. (1999) · Cancer Letters · doi:10.1016/s0304-3835(99)00020-8 · Cited by 56
Dietary regulation of P-gp function and expression
Zhang, W., Han, Y., Lim, S., & Lim, L. Y. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902997967 · Cited by 55
Cancer treatment: the combination of vaccination with other therapies
Andersen, M. H., Sørensen, R. B., Schrama, D., Svane, I. M., Becker, J. C., & Straten, P. T. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0480-y · Cited by 52
Pharmacogenomics of Drug-Metabolizing Enzymes and Drug Transporters in Chemotherapy
Bosch, T. M. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-205-2_5 · Cited by 51
Multidrug resistance in epilepsy: a pharmacogenomic update
Tate, S. K., & Sisodiya, S. M. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.10.1441 · Cited by 51
LEVOTHYROXINE UP-REGULATES P-GLYCOPROTEIN INDEPENDENT OF THE PREGNANE X RECEPTOR
Mitin, T., Moltke, L. L., Court, M. H., & Greenblatt, D. J. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.8.779 · Cited by 48
MDR1, Chemotherapy and chromatin remodeling
Baker, E. K., & El‐Osta, A. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.9.1101 · Cited by 48
Kühne, A., Tzvetkov, M. V., Hagos, Y., Lage, H., Burckhardt, G., & Brockmöller, J. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.03.026 · Cited by 47
Mohan, H. K., & Miles, K. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.055988 · Cited by 43
Influence of lipid lowering fibrates on P-glycoprotein activity in vitro
Adling-Ehrhardt, M., Lindenmaier, H., Burhenne, J., Haefeli, W. E., & Weiß, J. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.09.008 · Cited by 41
Seedhouse, C., Grundy, M. A., White, P., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1484 · Cited by 40
Helgason, H. H., Kruijtzer, C. M. F., Huitema, A. D. R., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603332 · Cited by 38
Meijer, O. C., Karssen, A. M., & de Kloet, E. R. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1780013 · Cited by 34
Sekine, I., Shimizu, C., Nishio, K., et al. (2009) · International Journal of Clinical Oncology · doi:10.1007/s10147-008-0813-z · Cited by 34
Barbet, J. L., Snook, T. S., Gay, J. M., & Mealey, K. L. (2008) · Veterinary Dermatology · doi:10.1111/j.1365-3164.2008.00725.x · Cited by 33
Drug–drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1)
Aszalós, A. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.022 · Cited by 32
Marguerite, V., Béri‐Dexheimer, M., Ortiou, S., Guéant, J., & Merten, M. D. (2007) · Cellular Physiology and Biochemistry · doi:10.1159/000110457 · Cited by 30
Chu, Z. E., Chen, J., Liau, C., Wang, H., Lin, Y., Yang, M., Chen, P., Gardner, E. R., Figg, W. D., & Sparreboom, A. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282f3fd2e · Cited by 27
Liu, Y., & Hunt, C. A. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9505-4 · Cited by 24
Lelong-Rebel, I. H., & CARDARELLI, C. O. (2005) · PubMed · Cited by 20
Expression and Induction of p-Glycoprotein-1 on Cultured Human Brain Endothelium
Male, D. K. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.101 · Cited by 13
Cited by
Multiplex assessment of protein variant abundance by massively parallel sequencing
Matreyek, K. A., Starita, L. M., Stephany, J. J., Martin, B., Chiasson, M. A., Gray, V. E., Kircher, M., Khechaduri, A., Dines, J. N., Hause, R. J., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0122-z · Cited by 436
Incidence and Prevalence of Drug-Resistant Epilepsy: A Systematic Review and Meta-analysis
Sultana, B., Panzini, M.-A., Veilleux Carpentier, A., Comtois, J., Rioux, B., Gore, G., Bauer, P. R., Kwon, C.-S., Jetté, N., Josephson, C. B., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011839 · Cited by 435
Silva, M. C., Nandi, G. A., Tentarelli, S., Gurrell, I. K., Jamier, T., Lucente, D., Dickerson, B. C., Brown, D. G., Brandon, N. J., & Haggarty, S. J. (2020) · Nature Communications · doi:10.1038/s41467-020-16984-1 · Cited by 157
The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer’s disease
Su, Q., Guo, J.-H., Zhang, Y.-L., Wang, J., & Zhang, Z.-N. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335829 · Cited by 91
Using machine learning to identify adverse drug effects posing increased risk to women
Chandak, P., & Tatonetti, N. P. (2020) · Patterns · doi:10.1016/j.patter.2020.100108 · Cited by 51
Metadata
- Authors
- Hodges, L. M., Markova, S. M., Chinn, L. W., Gow, J. M., Kroetz, D. L., Klein, T. E., & Altman, R. B.
- Venue
- Pharmacogenetics and Genomics
- Published
- 2011-03
- Volume
- 21
- Issue
- 3
- Pages
- 152-161
- ISSN
- 1744-6872 (ISSN-L)
- OpenAlex
- W1507788646
- Cited by
- 436
- References
- 134
- FWCI
- 8.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.